Beta Bionics
Update in progressBBNX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Beta Bionics is a medical device company developing and commercializing automated insulin delivery for diabetes. Its iLet Bionic Pancreas targets insulin-requiring individuals with type 1 diabetes and age 6+, while Patch Pump aims to deliver insulin without tubing. The company also works on Bihormonal iLet for insulin and glucagon, and iLet for insulin-dependent type 2 diabetes. Collaborations include Xeris for a glucagon formulation and Abbott for automated insulin delivery. Founded in 2015 and based in Irvine, California.
Company score
- Sentiment
- -0.05
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.07
- Governance
- -0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.03
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!